Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Cathie Wood Is Loading Up on These 3 Next-Gen Tech Stocks
10:49am, Thursday, 23'rd Apr 2026
CEO Eric Lefkofsky framed the trajectory plainly: “As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years,
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
06:51pm, Wednesday, 22'nd Apr 2026
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.42, indicating a +1.58% shift from the previous trading day.
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
01:30pm, Tuesday, 21'st Apr 2026
CRISPR Therapeutics plans to post clinical trial updates for multiple candidates this year. The company's stock could jump if it can impress the market.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
10:01am, Tuesday, 21'st Apr 2026
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Financial Analysis: CRISPR Therapeutics (NASDAQ:CRSP) and Femasys (NASDAQ:FEMY)
01:29am, Friday, 17'th Apr 2026
CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
06:51pm, Thursday, 16'th Apr 2026
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $55.72, marking a -1.83% move from the previous day.
CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months
03:35am, Wednesday, 15'th Apr 2026
CRISPR Therapeutics (NASDAQ: CRSP) CEO Sam Kulkarni told investors at the Needham Healthcare Conference that the company is moving into what he described as a "second phase" following the launch of Ca
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
07:11pm, Monday, 13'th Apr 2026
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
2 Billion Reasons to Love CRISPR Therapeutics Right Now
01:30pm, Monday, 13'th Apr 2026
CRISPR Therapeutics is still losing money, but it has an expanding pipeline. The biotech is seeing growing sales from its one product, Casgevy.
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
08:49am, Sunday, 12'th Apr 2026
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That's according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of
Wall Street Is Completely Wrong About These 5 Stocks
01:35pm, Thursday, 09'th Apr 2026
Steven Orr, Founder & CEO, Quasar Markets breaks down the five stocks Wall Street is mispricing and explains how he's finding real opportunities across AI, biotech, crypto and consumer right now.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 08'th Apr 2026
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area
06:30am, Wednesday, 08'th Apr 2026
CRISPR Therapeutics has a pair of candidates that could transform how we address certain risk factors for cardiovascular conditions. They aren't the only promising candidates in the pipeline, either.
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 07'th Apr 2026
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Vi
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?
04:43am, Tuesday, 07'th Apr 2026
CRISPR Therapeutics is the second largest holding in Cathie Wood's Ark Innovation ETF. Incoming clinical trial data could send the stock soaring this year.
